Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation
雾化维生素 A:开发高氧性肺损伤和支气管肺发育不良的预防方法,重点关注新生儿肺成熟
基本信息
- 批准号:10581259
- 负责人:
- 金额:$ 99.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAdultAerosolsAgeAll-Trans-RetinolAnimal ModelAnimalsAuthorization documentationAwardBiological AssayBiological MarkersBiotechnologyBronchopulmonary DysplasiaCanis familiarisChronic PhaseClinicClinicalClinical ResearchCollaborationsComplicationConfidential InformationDataData SetDevelopmentDoseDrug Delivery SystemsEffectivenessEngineeringEnteralFDA approvedFormulationFundingGene Expression RegulationGene ProteinsGenerationsGoalsGuidelinesHumanHyperoxiaInhalationInjectionsIntramuscularIntramuscular InjectionsLifeLong-Term CareLungMeasuresMedicalMedical centerMedicineModelingMorphologyNational Heart, Lung, and Blood InstituteNebulizerNeonatalNewborn InfantOralOrganOrphanOryctolagus cuniculusOutcomePathway interactionsPatientsPharmaceutical EconomicsPharmaceutical PreparationsPhasePhospholipidsPopulationPremature InfantPreventionProcessProductionProductivityProgram DevelopmentProteinsPublicationsPublishingPulmonary InflammationPulmonary function testsRattusRegimenResearchRetinopathy of PrematurityRiskRodentSafetyScienceSecureSepsisSerumSeveritiesSmall Business Innovation Research GrantStructure of parenchyma of lungSupplementationTestingTherapeuticToxic effectToxicologyUp-RegulationValidationVitamin AVitamin A DeficiencyWaterWorkabsorptionaerosolizedanimal dataauthoritychemical stabilityclinic readycommercializationcostdrug developmentdrug efficacydrug testingevaluation/testingfirst-in-humanin vivoinnovationinterestlamb modelliver injurylong-term sequelaelung developmentlung injurylung maturationmanufacturemeetingsneonatal sepsisneonatenovelnovel strategiesoxidative damagepatient populationpostnatalpre-clinicalprematurepreservationpreterm newbornpreventproduct developmentprotein expressionpulmonary functionreceptorreconstitutionresearch clinical testingretinyl palmitatescale upside effectsuccesssurfactant
项目摘要
Advent Therapeutics (Advent) is a biotech focusing on novel approaches to reformulate and optimize delivery
of legacy drugs with proven efficacy to address unmet medical needs of specific underserved and orphan patient
populations. Advent is developing an aerosol formulation of its proprietary, optimized water miscible vitamin A
(vitA) palmitate for non-invasive (inhaled) delivery to preterm infants to address vitA deficiency (VAD), and
prevent bronchopulmonary dysplasia (BPD), its most serious and costly complication. Prevention of BPD is the
focus of this Phase IIB/SMA application and a NHLBI topic of specific interest under this FOA, RFA-HL-23-008.
We will be building on the very significant data supported by our Phase I/II SBIR award with our innovative
inhaled vitA formulation that: 1) avoids the drawbacks of invasive intramuscular (IM) injections and absorption
limitations of current oral forms, overcoming significant hurdles for routine NICU utilization, and 2) provides direct-
to-target-organ delivery for increased efficacy- our in vivo data show significant benefit over IM dosing in
mitigating hyperoxic lung damage (in our BPD animal model), while providing adequate systemic delivery to also
treat VAD as discussed in the Research Strategy and in our recent publication (47).
In collaboration with Dr. Virender Rehan at Harbor-UCLA Medical Center, we have completed all Phase I
Specific Aims and are wrapping up Phase II Aims, demonstrating that inhaled vitA: 1) stimulates lung maturation
(assay of lung biomarkers showing upregulation of retinol receptors, surfactant protein and phospholipid
synthesis, as well as maturation biomarkers, while simultaneously raising serum vitA levels similar to IM dosing);
2) dramatically (vs IM) reduces hyperoxic lung tissue damage (assessment of lung tissue histomorphometry and
reduction of lung-injury biomarkers); and 3) preserves pulmonary function (preliminary longer-term PFT data).
In Phase IIB, we will further refine inhaled vitA dosing strategies for mitigating hyperoxic lung damage (BPD
prevention) in a step-wise approach by studying the well characterized premature lamb BPD model and proceed
with IND-enabling activities to be ready to begin first-in-man clinical studies in preterm infants at risk for
development of BPD. Phase IIb Specific Aims are: 1: Optimization of the dosing regimen of aerosolized vitA
for mitigating hyperoxic lung damage in a premature lamb BPD model, focusing on both the “neonatal” (acute
phase) timeframe, and also over the longer term (chronic phase) into “adulthood”, assessing similar biomarkers,
morphologic, and PFT evaluation as per Phase I/II. Aim 2: proceeding with drug manufacturing development
and scale-up of our formulation under stringent GLP and GMP controls. Aim 3: conducting GLP toxicology
studies in both small (rat) and large (dog) species to support clinic-readiness. Measures of success will be
generation of data supporting further development of our novel non-invasive therapy for preventing BPD (and
treating VAD), including a vitA formulation that meets adequate CMC requirements to proceed into the clinic,
and completion of GLP toxicology showing adequate safety for first-in-man studies in at-risk preterm neonates.
Advent Therapeutics(Advent)是一家专注于重新配制和优化递送的新方法的生物技术公司
已证明有效的传统药物,以解决特定服务不足和孤儿患者未满足的医疗需求
人口。Advent正在开发其专有的、优化的水溶性维生素A气雾剂配方
(vitA)棕榈酸酯,用于向早产儿非侵入性(吸入)递送,以解决vitA缺乏症(VAD),和
预防支气管肺发育不良(BPD),其最严重和昂贵的并发症。预防BPD是
IIB/SMA阶段申请的重点和本FOA中特别关注的NHLBI主题,RFA-HL-23-008。
我们将建立在非常重要的数据支持我们的第一/第二阶段SBIR奖与我们的创新
吸入的维生素A制剂:1)避免了侵入性肌内(IM)注射和吸收的缺点
目前口服形式的局限性,克服常规NICU使用的重大障碍,和2)提供直接-
靶器官给药以提高疗效-我们的体内数据显示,
减轻高氧肺损伤(在我们的BPD动物模型中),同时提供足够的全身递送,
按照研究策略和我们最近的出版物(47)中的讨论来治疗VAD。
在海港-加州大学洛杉矶分校医学中心的Virender Rehan博士的合作下,我们已经完成了第一阶段的所有工作,
具体目标和正在结束第二阶段的目标,证明吸入维生素A:1)刺激肺成熟
(显示视黄醇受体、表面活性剂蛋白和磷脂的上调的肺生物标志物的测定
合成,以及成熟生物标志物,同时提高血清维生素A水平,类似于IM给药);
2)显著(与IM相比)降低高氧肺组织损伤(肺组织组织形态计量学评估和
肺损伤生物标志物的减少);和3)保留肺功能(初步的长期PFT数据)。
在IIB期,我们将进一步完善吸入维生素A的剂量策略,以减轻高氧肺损伤(BPD
预防),通过研究表征良好的早产羔羊BPD模型,
与IND使能活动准备好开始在有风险的早产儿中进行首次人体临床研究
BPD的发展。IIb期的具体目标是:1:优化雾化维生素A的给药方案
用于减轻早产羔羊BPD模型中的高氧肺损伤,重点是“新生儿”(急性
阶段)时间范围内,并且还在较长期(慢性期)进入“成年期”,评估类似的生物标志物,
根据I/II期进行形态学和PFT评价。目标2:进行药物生产开发
并在严格的GLP和GMP控制下扩大我们的配方。目标3:开展GLP毒理学
在小型(大鼠)和大型(犬)物种中进行研究,以支持临床准备。衡量成功的标准将是
生成数据,支持进一步开发我们用于预防BPD的新型非侵入性疗法(以及
治疗VAD),包括满足足够的CMC要求以进入临床的vitA制剂,
并完成GLP毒理学研究,显示在高危早产儿中进行的首次人体研究具有充分的安全性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Craig Gelfand其他文献
Craig Gelfand的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Craig Gelfand', 18)}}的其他基金
Aerosolized Vitamin A: Impact on Neonatal Lung Maturation, Hyperoxic Lung Injury and Bronchopulmonary Dysplasia
雾化维生素 A:对新生儿肺成熟、高氧性肺损伤和支气管肺发育不良的影响
- 批准号:
10010762 - 财政年份:2018
- 资助金额:
$ 99.51万 - 项目类别:
Aerosolized Vitamin A: Impact on Neonatal Lung Maturation, Hyperoxic Lung Injury and Bronchopulmonary Dysplasia
雾化维生素 A:对新生儿肺成熟、高氧性肺损伤和支气管肺发育不良的影响
- 批准号:
10238056 - 财政年份:2018
- 资助金额:
$ 99.51万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 99.51万 - 项目类别:
Research Grant